Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants are a continuous threat to human life and prosperity. An urgent need remains for simple and fast tests that reliably detect active infections with SARS-CoV-2 and its variants in asymptomatic and presymptomatic carriers. Here we introduce a simple and rapid activity-based diagnostic (ABDx) test that identifies SARS-CoV-2 infections by measuring the activity of a viral enzyme, Papain-Like protease (PLpro). The test system consists of a peptide that fluoresces when cleaved by SARS PLpro that is active in crude, unprocessed lysates from human tongue scrapes and saliva. Test results are obtained in 30 minutes or less using widely available fluorescence plate readers, or a battery-operated portable instrument for testing at point of care (PoC) sites and in low-resource and hard to reach populations. Proof-of-concept was obtained in a clinical study on clinical specimens collected from patients with COVID-19 like symptoms who tested positive (n=10) or negative (n=10) with diagnostic LIAT RT-PCR using nasal mid turbinate swabs. When saliva from these patients was tested with in-house endpoint RT-PCR only 3 specimens were negative and 17 were positive. PLpro activity correlated in 17 of these cases (3 out of 3 negatives and 14 out of 16 positives), with one invalid specimen. Despite the small number of samples, the agreement was significant (p value = 0.01). In one presumptive false positive patient viral RNA was detected in saliva 5 days later by endpoint RT-PCR. Two false negatives were detected, one from a sample with a late Ct value of 35 in diagnostic RT-PCR, indicating that an active infection was no longer present. The PLpro activity assay is easily scalable and expected to detect all viable SARS-CoV-2 variants and recombinants, making it attractive as a screening and surveillance tool. Additionally, we show feasibility of the platform as a new homogeneous phenotypic assay for rapid screening of SARS-CoV-2 antiviral drugs and neutralizing antibodies.

Mesa Photonics holds two utility patents covering diagnostics of SARS-CoV-2 infections and antiviral screening based on PLpro activity, with FHR as inventor. The other authors declare no conflict of interest.

The research was funded by the Department of Defense, Defense Logistics Agency (SP4701-21-C-0054) to Mesa Photonics.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This project was approved by the University of New Mexico Health Sciences Center Human Research Protection Program. Review and approval were obtained from the UNM Institutional Review Board (IRB) under Study Numbers 22-373 and 22-038.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors